Opinion: For AI to Have Impact, the Industry Must Align on Data

Why It Matters

Without unified data standards, AI‑driven insights may mislead drug developers, delaying breakthroughs and increasing risk. Robust, shared datasets enable regulators and companies to leverage AI for quicker, more reliable therapeutic pipelines.

Key Takeaways

• AI performance hinges on clean, well‑structured drug discovery data
• Rich metadata at experiment start multiplies future model efficiency
• Industry still lacks unified FAIR standards for pre‑clinical and clinical datasets
• FDA draft guidance on NAMs may unlock broader non‑animal model adoption
• Collaborative data harmonization can shorten timelines for first‑in‑class drugs

Pulse Analysis

The surge of artificial intelligence in biopharma is reshaping every stage of drug development, from molecule design to regulatory review. Tools like the FDA's Elsa illustrate how generative AI can parse massive trial datasets, but the technology’s accuracy is only as good as the underlying data. Inconsistent metadata, varied file formats, and fragmented data silos create blind spots that can magnify errors when models extrapolate findings across studies. Companies that embed rigorous data‑curation practices early—capturing rich metadata and enforcing consistent formatting—position themselves to extract reliable, high‑impact insights from AI.

A critical barrier remains the industry’s fragmented approach to data standards. While clinical data benefit from CDISC specifications and non‑clinical studies use SEND, there is no universal framework that makes discovery‑phase data FAIR—findable, accessible, interoperable, and reusable. Consortia led by CROs, academic partners, and technology firms are piloting harmonization protocols, yet widespread adoption lags. Establishing cross‑functional teams that bridge experimental scientists with data engineers can embed FAIR principles at the source, turning each experiment into a reusable asset for future predictive models.

Regulatory momentum is finally aligning with these technical needs. The FDA's recent draft guidance on non‑animal models (NAMs) clarifies validation pathways, encouraging broader use of organoids, microphysiological systems, and AI‑driven toxicology predictions. Coupled with Elsa's deployment, this signals a shift toward data‑centric decision‑making that could compress development timelines for first‑in‑class therapies. Companies that proactively share clean, harmonized datasets through trusted safe‑harbor platforms will likely reap competitive advantages, accelerating drug candidates from bench to bedside while reducing reliance on animal testing.